Cantor Fitzgerald restated their overweight rating on shares of AscendisPharma A/S (NASDAQ:ASND – Free Report) in a report published on Monday, Benzinga reports. They currently have a $170.00 ...
Wedbush analyst Liana Moussatos reiterated a Buy rating on AscendisPharma (NASDAQ:ASND) on Monday, setting a price target of $209, which is approximately 33.55% ...
The company’s shares opened today at $7.62. Ahmad covers the Healthcare sector, focusing on stocks such as Alnylam Pharma, AscendisPharma, and Ultragenyx Pharmaceutical. According to TipRanks, ...
Results that may be inaccessible to you are currently showing.